Cytokinetics cheers a PhIII readout for their heart drug developed with Amgen, but analysts and investors aren't joining the party
Fifteen years after it entered the clinic, Amgen $AMGN and Cytokinetics’ closely watched heart drug popped out the other side, meeting the primary endpoint in a Phase III study. But it missed key secondary endpoints including reduction in cardiovascular death — and Cytokinetics CEO Robert Blum said whether they’ll approach regulators is still up for discussion.
“It seems reasonable to assume that that will occur. But we’ve not made any decisions on that,” Blum told Endpoints News. While the companies celebrated the results at this year’s AHA, Cytokinetics’ stock $CYTK slipped just over 5% before the bell.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.